top of page
Advancing Innovations to Promote Female Reproductive Health
First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for mucosal health
Proprietary intravaginal ring technologies for sustained delivery of small molecules to biomacromolecules
Unparalleled safety from topical delivery
Our lead contraceptive mAb candidate is published in Science Translational Medicine. UNC Chapel Hill Press release. Media coverage:
The Scientist, Wired Magazine, MedScape, WRAL TechWire.
Inhalon, our sister company, announces partnership with Celltrion and initiates Phase 1 and 2 clinical trial.
March 11th, 2021 - Mucommune in consortium that initiates first-ever clinical trial for a contraceptive mAb (ClinicalTrials.gov, NCT04731818).
bottom of page